These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 17560766)

  • 1. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.
    Savina I; Beninger RJ
    Schizophr Res; 2007 Aug; 94(1-3):128-38. PubMed ID: 17560766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cognition, schizophrenia and the effect of antipsychotics].
    Stip E
    Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics.
    Wasserman JI; Barry RJ; Bradford L; Delva NJ; Beninger RJ
    Psychopharmacology (Berl); 2012 Jul; 222(1):173-83. PubMed ID: 22237855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LORETA functional imaging in antipsychotic-naive and olanzapine-, clozapine- and risperidone-treated patients with schizophrenia.
    Tislerova B; Brunovsky M; Horacek J; Novak T; Kopecek M; Mohr P; Krajca V
    Neuropsychobiology; 2008; 58(1):1-10. PubMed ID: 18781085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
    Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
    J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model of anticholinergic activity of atypical antipsychotic medications.
    Chew ML; Mulsant BH; Pollock BG; Lehman ME; Greenspan A; Kirshner MA; Bies RR; Kapur S; Gharabawi G
    Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
    Crespo-Facorro B; Rodríguez-Sánchez JM; Pérez-Iglesias R; Mata I; Ayesa R; Ramirez-Bonilla M; Martínez-Garcia O; Vázquez-Barquero JL
    J Clin Psychiatry; 2009 Apr; 70(5):717-29. PubMed ID: 19389335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of clozapine and risperidone on spatial working memory in schizophrenia.
    McGurk SR; Carter C; Goldman R; Green MF; Marder SR; Xie H; Schooler NR; Kane JM
    Am J Psychiatry; 2005 May; 162(5):1013-6. PubMed ID: 15863811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
    Bilder RM; Goldman RS; Volavka J; Czobor P; Hoptman M; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Kunz M; Chakos M; Cooper TB; Horowitz TL; Lieberman JA
    Am J Psychiatry; 2002 Jun; 159(6):1018-28. PubMed ID: 12042192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
    Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
    BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
    Citrome L; Volavka J; Czobor P; Sheitman B; Lindenmayer JP; McEvoy J; Cooper TB; Chakos M; Lieberman JA
    Psychiatr Serv; 2001 Nov; 52(11):1510-4. PubMed ID: 11684748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment.
    Hong CJ; Chen TT; Bai YM; Liou YJ; Tsai SJ
    World J Biol Psychiatry; 2012 Jan; 13(1):22-9. PubMed ID: 21375366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
    Light GA; Geyer MA; Clementz BA; Cadenhead KS; Braff DL
    Am J Psychiatry; 2000 May; 157(5):767-71. PubMed ID: 10784470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
    Krakowski MI; Czobor P; Nolan KA
    J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics.
    Han M; Zhang XY; Chen DC; Tan YL; Song CS; Yu YH; Huang XF
    Int Clin Psychopharmacol; 2015 Mar; 30(2):89-95. PubMed ID: 25568968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
    Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
    Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
    Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
    Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.
    Adler LE; Olincy A; Cawthra EM; McRae KA; Harris JG; Nagamoto HT; Waldo MC; Hall MH; Bowles A; Woodward L; Ross RG; Freedman R
    Am J Psychiatry; 2004 Oct; 161(10):1822-8. PubMed ID: 15465979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study].
    Mayoral F; Montejo AL; Bousoño M; González-Torres MA; Olivares JM; Ros S; Sanjuán J; Escobar R; Lara N
    Actas Esp Psiquiatr; 2006; 34(1):7-15. PubMed ID: 16525900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.